Sacubitril-valsartan in Patients With Heart Failure.

• A 3-month, prospective interventional study, which will include 60 patients with heart failure reduced ejection fraction, patients, will be consecutively randomized into two groups, the first group (n=30) will be given Sacubitril-valsartan twice daily and the second group (n=30) on standard treatment of heart failure.
• Approval will be obtained from Research and Ethics Committee of Faculty of Pharmacy, Damanhour University. Patients will provided written informed consent and will be checked for inclusion and exclusion criteria.
• All patients will undergo analysis of inflammatory biomarkers such as: NT-proBNP, Galectin-3 and GDF-15 at beginning of the study and after 3 months of the study.
• Echocardiography study before and after the study focusing on:

Measurement of parameters such as: Left atrial diameter (LAD), basic left ventricular dimensions (EDD and ESD), Ejection fraction (EF%).

• Follow up will be performed for assessing:

• MACE such as MI, stroke, HF, or death.
• LV Echocardiography improvements of any of basic Echo parameters.
• Assessment of New York Heart association (NYHA) class.

Outcomes: all patients will be followed up for 3 months for:

• 1ry outcomes: A.Major Adverse Cardiovascular Events (MACE) such as MI, stroke or death. B.Heart failure hospitalization C.LV Echocardiography improvements of any of basic Echo parameters such as: Left atrial diameter (LAD), basic left ventricular dimensions (EDD and ESD), Ejection fraction (EF%).
• 2ry outcomes: Change in inflammatory markers such as: NT-proBNP, GDF-15 and Galectin-3.

Inclusion criteria

• Age ≥ 18 years old for both genders.
• LV ejection fraction (LVEF) ≤40%.
• Heart failure patients with NYHA grade II-IV.

Exclusion criteria

• CKD with GFR < 20 ml/min/1.73
• Serum potassium < 5.5 mmol / L.
• Pregnant or lactating women
• Active infection.
• Congenital heart disease.
• Autoimmune disorders or connective tissue disorders.
• Severe hepatic dysfunction.